GYKI-52895
From Wikipedia, the free encyclopedia
Systematic (IUPAC) name | |
---|---|
4-{13-methyl-4,6-dioxa-11,12-diazatricyclo[7.5.0.03,7]tetradeca-1,3(7),8,10-tetraen-10-yl}aniline | |
Clinical data | |
Legal status | ? |
Identifiers | |
CAS number | 869360-93-0 |
ATC code | ? |
PubChem | CID 3539 |
ChemSpider | 3418 |
KEGG | C15094 |
Synonyms | 4-(8,9-Dihydro-8-methyl-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepin-5-yl)benzenamine |
Chemical data | |
Formula | C17H17N3O2 |
Mol. mass | 295.34 |
SMILES
| |
| |
(what is this?) (verify) | |
GYKI-52895 is a drug which is a 2,3-benzodiazepine derivative. Unlike other similar drugs, GYKI-52895 is a selective dopamine reuptake inhibitor,[1][2] which presumably would produce stimulant effects in vivo.
See also
- Benzodiazepine
- Substituted methylenedioxyphenethylamine
References
- ↑ Horváth K, Szabó H, Pátfalusi M, Berzsenyi P, Andrási F. Pharmacological Effects of GYKI 52895, a New Selective Dopamine Uptake Inhibitor. European Journal of Pharmacology. 1990; 183(4):1416-1417.
- ↑ Huang CL, Chen HC, Huang NK, Yang DM, Kao LS, Chen JC, Lai HL, Chern Y. Modulation of Dopamine Transporter Activity by Nicotinic Acetylcholine Receptors and Membrane Depolarization in Rat Pheochromocytoma PC12 Cells. Journal of Neurochemistry. 1999; 72(6): 2437–2444.
|
|
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.